Goldman Sachs Initiates Coverage On Rhythm Pharmaceuticals with Sell Rating, Announces $18 Price Target

Goldman Sachs analyst Graig Suvannavejh initiates coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Sell rating and a $18 price target.

Benzinga · 01/08/2020 11:43

Goldman Sachs analyst Graig Suvannavejh initiates coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Sell rating and a $18 price target.